Multiple MyelomaSide-Effects Management

Potential Side Effects and How to Treat

Jack Aiello shares his experience on orals, and the significance of informing patients of the side effects and mitigating them.
Video Library – February 5, 2016
Jack Aiello
Patient Advocate
San Jose, CA
Multiple myeloma survivor

It's actually been a long time since my medical team gave me some information with respect to an oral treatment. That said, what is helpful is that they gave me the detailed understanding of things I previously discussed. When should I be taking it, how often?

For example, I was on an oral treatment called thalidomide. Thalidomide tended to make you sleepy. The recommendation was take it before you go to bed and you will get a fine night's sleep, which you did. That was an important recommendation as opposed to taking it in the morning and you're sleepwalking through the day.

I think that it's also important that they at least make you aware of potential side effects. The issue if someone says, "Well, this is going to cause some stomach ache," is that with the patient, once they take it, if they get a stomach ache, they make think, "Oh, that drug has caused it. It may have. It's more important to have complete information.

If I might get a suspected skin rash, if I might have some type of other side effect, it's important for doctors to share that information and furthermore, what to do if that happens.

There may be drugs that I should be taking prophylactically to prevent those side effects from occurring and maybe I am. Maybe those dosages should be increased, or not. Doctors can help you make sure that the side effects you experience are minimal.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
Oral HealthTransplantsLymphomaLeukemiaMultiple Myeloma
Bone Marrow Transplants and Oral Health for Patients with Blood Cancers
By Jill Meyer-Lippert, RDH, Amanda Swiecichowski, RN, BSN, CHPN
Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant.
FDA Approvals, News & UpdatesMultiple Myeloma
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
In December 2020, the FDA approved Xpovio (selinexor), for use in combination with the proteasome inhibitor Velcade (bortezomib) and the steroid dexamethasone, for the treatment of adults with multiple myeloma who have received at least 1 previous therapy. Xpovio was previously approved for several types of lymphoma.
Last modified: October 31, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.